Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial

BACKGROUND: Most children with medulloblastoma fall within the standard-risk clinical disease group defined by absence of high-risk features (metastatic disease, large-cell/anaplastic histology, and MYC amplification), which includes 50–60% of patients and has a 5-year event-free survival of 75–85%....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Lancet Oncol
Egile Nagusiak: Goschzik, Tobias, Schwalbe, Edward C, Hicks, Debbie, Smith, Amanda, zur Muehlen, Anja, Figarella-Branger, Dominique, Doz, François, Rutkowski, Stefan, Lannering, Birgitta, Pietsch, Torsten, Clifford, Steven C
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Lancet Pub. Group 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6262170/
https://ncbi.nlm.nih.gov/pubmed/30392813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30532-1
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak